High-throughput investigation of molecular and cellular biomarkers in NMOSD
Open Access
- 1 September 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
Abstract
Objective To identify candidate biomarkers associated with neuromyelitis optica spectrum disorder (NMOSD) using high-throughput technologies that broadly assay the concentrations of serum analytes and frequencies of immune cell subsets. Methods Sera, peripheral blood mononuclear cells (PBMCs), and matched clinical data from participants with NMOSD and healthy controls (HCs) were obtained from the Collaborative International Research in Clinical and Longitudinal Experience Study NMOSD biorepository. Flow cytometry panels were used to measure the frequencies of 39 T-cell, B-cell, regulatory T-cell, monocyte, natural killer (NK) cell, and dendritic cell subsets in unstimulated PBMCs. In parallel, multiplex proteomics assays were used to measure 46 serum cytokines and chemokines in 2 independent NMOSD and HC cohorts. Multivariable regression models were used to assess molecular and cellular profiles in NMOSD compared with HC. Results NMOSD samples had a lower frequency of CD16(+)CD56(+) NK cells. Both serum cohorts and multivariable logistic regression revealed increased levels of B-cell activating factor associated with NMOSD. Interleukin 6, CCL22, and CCL3 were also elevated in 1 NMOSD cohort of the 2 analyzed. Multivariable linear regression of serum analyte levels revealed a correlation between CX3CL1 (fractalkine) levels and the number of days since most recent disease relapse. Conclusions Integrative analyses of cytokines, chemokines, and immune cells in participants with NMOSD and HCs provide congruence with previously identified biomarkers of NMOSD and highlight CD16(+)CD56(+) NK cells and CX3CL1 as potential novel biomarker candidates.This publication has 43 references indexed in Scilit:
- Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin lossActa Neuropathologica, 2012
- Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytesProceedings of the National Academy of Sciences of the United States of America, 2011
- Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximabNeurology, 2011
- Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in miceBrain, 2010
- B-CELL ACTIVATING FACTOR OF THE TNF FAMILY IS UPREGULATED IN NEUROMYELITIS OPTICANeurology, 2010
- Neuromyelitis optica: Passive transfer to rats by human immunoglobulinBiochemical and Biophysical Research Communications, 2009
- Intrathecal pathogenic anti–aquaporin‐4 antibodies in early neuromyelitis opticaAnnals of Neurology, 2009
- BAFF Overexpression Is Associated with Autoantibody Production in Autoimmune DiseasesAnnals of the New York Academy of Sciences, 2005
- The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age‐related macular degenerationThe FASEB Journal, 2004
- Reduced Competitiveness of Autoantigen-Engaged B Cells due to Increased Dependence on BAFFImmunity, 2004